Cell-Based Therapies for Stroke: Are We There Yet?

Stroke is the second leading cause of death and physical disability, with a global lifetime incidence rate of 1 in 6. Currently, the only FDA approved treatment for ischemic stroke is the administration of tissue plasminogen activator (tPA). Stem cell clinical trials for stroke have been underway fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Krause, Mirja, Phan, Thanh G., Ma, Henry, Sobey, Christopher G., Lim, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603096/
https://www.ncbi.nlm.nih.gov/pubmed/31293500
http://dx.doi.org/10.3389/fneur.2019.00656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603096/
https://www.ncbi.nlm.nih.gov/pubmed/31293500
http://dx.doi.org/10.3389/fneur.2019.00656

Ejemplares similares